WallStSmart

nVent Electric PLC (NVT)vsVertex Pharmaceuticals Inc (VRTX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Vertex Pharmaceuticals Inc generates 182% more annual revenue ($12.22B vs $4.33B). VRTX leads profitability with a 35.5% profit margin vs 11.4%. NVT appears more attractively valued with a PEG of 1.76. VRTX earns a higher WallStSmart Score of 66/100 (B-).

NVT

Buy

55

out of 100

Grade: C-

Growth: 6.7Profit: 6.5Value: 2.7Quality: 5.0

VRTX

Strong Buy

66

out of 100

Grade: B-

Growth: 8.0Profit: 9.0Value: 6.7Quality: 8.0
Piotroski: 3/9Altman Z: 3.62
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

NVTSignificantly Overvalued (-72.1%)

Margin of Safety

-72.1%

Fair Value

$65.53

Current Price

$173.39

$107.86 premium

UndervaluedFair: $65.53Overvalued
VRTXUndervalued (+56.6%)

Margin of Safety

+56.6%

Fair Value

$989.67

Current Price

$448.29

$541.38 discount

UndervaluedFair: $989.67Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

NVT1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
53.5%10/10

Revenue surging 53.5% year-over-year

VRTX6 strengths · Avg: 9.7/10
Profit MarginProfitability
35.5%10/10

Keeps 36 of every $100 in revenue as profit

Operating MarginProfitability
38.1%10/10

Strong operational efficiency at 38.1%

EPS GrowthGrowth
61.4%10/10

Earnings expanding 61.4% YoY

Altman Z-ScoreHealth
3.6210/10

Safe zone — low bankruptcy risk

Market CapQuality
$107.87B9/10

Large-cap with strong market position

Return on EquityProfitability
24.2%9/10

Every $100 of equity generates 24 in profit

Areas to Watch

NVT3 concerns · Avg: 2.7/10
PEG RatioValuation
1.764/10

Expensive relative to growth rate

P/E RatioValuation
58.8x2/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
-59.5%2/10

Earnings declined 59.5%

VRTX3 concerns · Avg: 3.7/10
PEG RatioValuation
2.104/10

Expensive relative to growth rate

P/E RatioValuation
25.3x4/10

Moderate valuation

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : NVT

The strongest argument for NVT centers on Revenue Growth. Revenue growth of 53.5% demonstrates continued momentum.

Bull Case : VRTX

The strongest argument for VRTX centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 35.5% and operating margin at 38.1%.

Bear Case : NVT

The primary concerns for NVT are PEG Ratio, P/E Ratio, EPS Growth. A P/E of 58.8x leaves little room for execution misses.

Bear Case : VRTX

The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.

Key Dynamics to Monitor

NVT profiles as a growth stock while VRTX is a mature play — different risk/reward profiles.

NVT carries more volatility with a beta of 1.32 — expect wider price swings.

NVT is growing revenue faster at 53.5% — sustainability is the question.

VRTX generates stronger free cash flow (1.3B), providing more financial flexibility.

Bottom Line

VRTX scores higher overall (66/100 vs 55/100), backed by strong 35.5% margins. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

nVent Electric PLC

INDUSTRIALS · ELECTRICAL EQUIPMENT & PARTS · USA

nVent Electric plc designs, manufactures, markets, installs and services electrical connection and protection products in the United States, Canada, Western and Eastern Europe included in the European Union, China, Eastern Europe not included in the European Union, America Latin, Middle East, Southeast Asia, Australia and Japan. The company is headquartered in London, the United Kingdom.

Vertex Pharmaceuticals Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.

Want to dig deeper into these stocks?